<DOC>
	<DOCNO>NCT01772043</DOCNO>
	<brief_summary>We utilize Cooperative International Neuromuscular Research Group ( CINRG ) network collect store tissue blood patient Duchenne muscular dystrophy ( DMD ) specific genetic mutation within dystrophin gene could treat antisense oligonucleotide ( AO ) drug .</brief_summary>
	<brief_title>Duchenne Muscular Dystrophy Tissue Bank Exon Skipping</brief_title>
	<detailed_description>The purpose tissue bank collect blood skin sample participant diagnose Duchenne muscular dystrophy ( DMD ) carry one nine specific change dystrophin gene . The specific dystrophin change interested study would work exon-skipping therapy patient DMD , specifically deletion follow exon : 10-52 , 13-50 , 29-50 , 43-52 , 44 , 43-50 , 45-50 , 45-52 , 46 , 46-47 , 46-48 , 46-49 , 46-51 , 46-53 , 46-55 , 46-60 , 47-50 , 47-52 , 48-50 , 49-50 , 50 , 52 , 52-63 , 48-52 , 49-52 , 50-52 . These blood skin sample hold tissue bank Carolinas Medical Center future DMD research .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Age 4 Diagnosis DMD confirm outofframe dystrophin gene deletion could correct skip exon 45 , 51 , 53 base past genetic testing . Investigator assessment inability comply blood skin sample collection</criteria>
	<gender>Male</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>muscular dystrophy</keyword>
	<keyword>tissue bank</keyword>
</DOC>